Skip to main content
Fig. 5 | Antimicrobial Resistance & Infection Control

Fig. 5

From: Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Fig. 5

Results from probabilistic sensitivity analysis for CAZ-AVI sequence vs. Ceftolozane/Tazobactam sequence, on cost-effectiveness acceptability curve.

Abbreviations: CAZ-AVI ceftazidime-avibactam, QALY quality-adjusted life year.

CAZ-AVI sequence: CAZ-AVI plus metronidazole, followed by colistin + tigecycline + high-dose meropenem.

Ceftolozane/tazobactam sequence: Ceftolozane/tazobactam plus metronidazole, followed by colistin + tigecycline + high-dose meropenem

Back to article page

Antimicrobial Resistance & Infection Control

ISSN: 2047-2994

Contact us